The Science is Coming as Fish Says - Fight Prostate Ca...

Fight Prostate Cancer

2,801 members1,030 posts

The Science is Coming as Fish Says

GreenStreet profile image
11 Replies

Just realised I posted on wrong community (LoL.) The AZD5069 and enzaltutamide trial has been widely reported in the UK press. Very small sample size to check the concept but it targets white myeloid blood cells which apparently can fuel tumour growth. The drug combo works is designed to block the CXCR2 receptor and try to switch of the growth. Around 24% in a small sample showed either tumour reduction or blocked growth. De Bono and Prostate Cancer UK (which I support) are involved. The trial was conducted with men who had exhausted other treatment options. Still seems early days before we see it mainstream. We really need to find a way of safely fast tracking promising developments.

Best wishes to all on here.

Written by
GreenStreet profile image
GreenStreet
To view profiles and participate in discussions please or .
Read more about...
11 Replies
NPfisherman profile image
NPfisherman

Greenstreet,

Thanks for posting this info...I do say that a bit, don't I... Yes, the wrong community.... the less moderated ... lol...

dailyreporter.esmo.org/esmo...

Freaking Johann de Bono is the man !!! Love that guy...

It's what I keep saying that attacking AR needs to be less the focus, and more drugs that can be used to attack other areas, and can be combined with other drugs... hopefully, getting to a point, where there is a 3 drug combo and stable disease...

The problem: Small biotechs do not have the 50 million needed to do phase III... Big Pharma waits on the sidelines to get a bargain.... and ... people die...

The Science is Coming !!! .. but we need ways to get the completed Phase IIs off the sidelines and on to Phase III...

Don Pescado

GreenStreet profile image
GreenStreet in reply to NPfisherman

Thanks for posting the link. My technical competence is not very high. Originally I posted on the moderated site rather than this one which was not what I intended. I don’t even have the excuse of ADT because I am currently “on holiday “ . I noticed what you found dated to last year and I saw this too. For some reason the U.K. press has picked up on it now a year later and de Bono was on national radio this morning. Fully agree on combos doing different things and contributing to the whole. De Bono was also talking about the desirability of bringing forward some of these treatments to see if they give a better benefit if used earlier in the sequence. The science is coming. Hope you are well my friend.

NPfisherman profile image
NPfisherman in reply to GreenStreet

Glad to put it up...You may have the excuse of ADT still, depends on when you stopped...Still having some "hot flash" activity and took my last Eligard in March... brain fog is better...

Enjoy the holiday...

Fish

KocoPr profile image
KocoPr in reply to GreenStreet

You said one of the keys! Treatments earlier. It is so wrong for the FDA to not allow these drugs to be used earlier in treatments period! The big pharma needs results as quick as possible so they target Castrate Resistant patients.

NPfisherman profile image
NPfisherman in reply to KocoPr

KocoPr,

It kinda gets beyond that... MCRPC is a killer, where MHSPC is not... I know... the drugs can kill with increased risk for stroke and heart attacks in either case... I think Big Pharma pursues both, but looks at MCRPC first, because if it works in that case, then it is almost assured it will work in MHSPC... no resistance... plus, the increased cash flow is icing on the cake.. In the meantime, people progress at the MHSPC level... Big Pharma plays the tune, and we are forced to dance to it..

IMHO... FWIW...

Fish

KocoPr profile image
KocoPr in reply to NPfisherman

True statements but how come mhspc patients can’t get drugs because it wasn’t trialed on that earlier situation? Im sure big pharma would want it at the same time insurance would deny it. The FDA has to approve it for earlier use then insurance would have to cover it.

Maxone73 profile image
Maxone73 in reply to KocoPr

I suppose is the same everywhere, my MO said (in Italian and with a funny thick Roman accent) “these f##king bureaucrats of AIFA are always trying to stop me from doing my job”, AIFA is the equivalent of FDA, because darolutamide is paid by the national system if used alone or in double therapy but not yet in triplet….so Bayer basically inserted me in ARASENS trial and they are sending the pills for free while I am in triplet with chemo and adt….laziness? No will to take on responsibilities?? Bah!

NPfisherman profile image
NPfisherman in reply to KocoPr

Exactly right... This needs streamlined and sooner rather than later... While the system fiddles, people can worsen significantly. Base logic says if it works on the worst disease form, then the lesser is kind of a no brainer...

NPfisherman profile image
NPfisherman in reply to KocoPr

We dance to everyone's tune... Insurance.... Big Pharma... the Medical Community...I am sure that "right to try" is no easy route for patients, but it should be... It is why I say things are overdue for a revision.. Why shouldn't we be able to get to a 5 year survival rate of 50% in Stage IV Prostate Cancer?? We are around 32% now... maybe if everyone was treated at least with doublet therapy at the start, then we would be there... Where is the AUA on getting it done ??

Fish

lcfcpolo profile image
lcfcpolo

Thanks for posting. A friend just sent me a copy of the article in today's Daily Mail. I'm on Enzalutamide at the moment. It would be great if they said let's add it into the treatment mix now before I become castrate resistance. This does look promising for some guys in the future who are diagnosed.

GreenStreet profile image
GreenStreet in reply to lcfcpolo

Fully agree. 👍

You may also like...

New strategies against bone metastases from prostate cancer - Science Daily

metastases are different, providing different drug targets and suggesting different treatments . ....

Fish consumption and PCa Mortality. A meta-analysis.

risk} was 0.55 ... for prostate cancer mortality and 0.84 ... for prostate cancer progression,...

Indomethacin - resenisitize to Enza

to resensitize to Enza by blocking CRXR7 thus indirectly AR-V7. The trial was started in 2018,...

0VM-200 clinical trial

this first in human trial has a base at my hospital in UK. Phase 1 trials are scary of course .....

Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy

potential feasibility of vitamin D metabolism-blocking therapy in various types of human...